A Phase 1/2 interventional study of Vancomycin (IV) in Healthy Volunteer, Hypersensitivity Reactions and Vancomycin, sponsored by Johns Hopkins University. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-27.
Sponsored by Johns Hopkins University · Phase 1/2, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 300 studies in Hypersensitivity with a site in United States — 32 open to participants now, 40 under way, 1 of them phase 3. Hypersensitivity · United States.
Among the 300 studies in Hypersensitivity with a site in United States, this one is the 166th largest by planned enrollment of the 220 interventional ones that give a count, is one of 10 that started in 2026, is one of 13 in phase 1/2, reaches primary completion later than 14 of the 38 other live ones, and was the 298th registered.
1,056 studies on the registry are indexed under Hypersensitivity; 150 are open to participants now.
Browse Hypersensitivity studies →32 of the 300 studies in Hypersensitivity with a site in United States are open now. Recruiting first, the newest first:
Mayo Clinic · Sites in United States
Ages 12+
Lumicell, Inc. · Sites in United States
Ages 18+
National Institute of Allergy and Infectious Diseases (NIAID) · Sites in United States
Ages 12–50
National Institute of Allergy and Infectious Diseases (NIAID) · Sites in United States
Ages 12 mo–17 yrs
Qifeng Zhang · Sites in United States, China
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 101 Hypersensitivity studies recruiting now, 37 (37%) set no upper age limit and 52 (51%) stop at 75 or younger; 56 take children under 18; 37 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
300 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 44 · Phase 2 63 · Phase 3 41 · Phase 4 18
First in 1996; this study’s year is marked. 10 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 25 is below the median of 73 across 691 interventional studies indexed under Hypersensitivity.
Median enrollment 60 across the 220 interventional studies, 200 across the 76 observational. Of the 243 that completed or were terminated, 104 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
117 of 300 have an industry lead sponsor. The 10 most frequent:
Johns Hopkins University is the lead sponsor of 1,816 studies on the registry; 315 are open to participants now.
Of its 208 completed or terminated interventional studies of FDA-regulated products, 144 (69%) have results posted.
Johns Hopkins University has 8 studies filed under Hypersensitivity — fewer than ten, so there is no comparison to draw.
11 of the studies in Hypersensitivity with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07003919Phase 3DBV TechnologiesSafety Study of Viaskin® Peanut Patch in Peanut-Allergic Children 1 Through 3 Years of Age (COMFORT Toddlers) | 2026-11 |
| NCT05584488Columbia UniversityAllergy and Immunology Natural History Study | 2027-01 |
| NCT07447869National Institute of Allergy and Infectious Diseases (NIAID)LYmph Node eXamination in Cat Allergen Immunotherapy | 2027-01-27 |
| NCT03914664Vanderbilt University Medical CenterNeural Correlates of Sensory Phenomena in Tourette Syndrome | 2027-02-28 |
| NCT06834165ARS Pharmaceuticals, Inc.Study Evaluating the Safety and Efficacy of Neffy or Intramuscular Adrenalin in Patients With Allergic Reactions After Oral Food Challenge or Allergen Immunotherapy | 2027-04 |
Add all 11 to your calendar (.ics) → With an account.
Among the 300 studies in Hypersensitivity with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to investigate biomarkers of non-IgE-mediated immediate hypersensitivity reactions during infusion of intravenous vancomycin. The main question it aims to answer is:
Participants will:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The other ingredients in a medicine besides the active drug, such as fillers, colours or preservatives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colours or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
single infusion of vancomycin in healthy volunteers
Drug: Vancomycin (IV)
single infusion of vancomycin in healthy volunteers
Serum vancomycin concentration (mg/mL)
The concentration of vancomycin in serum (in mg/mL) associated with an infusion reaction
Time frame: 30 minutes
Started May 2026 (actual). Primary completion is estimated for May 2027, 12 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Vancomycin